María Silvia Bianchi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
María Silvia Bianchi has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Mónica Beatriz Frungieri
Instituto de Biología y Medicina Experimental, IBYME-CONICET, Ciudad de Buenos Aires 1428, Argentina
2 shared publications - Alina Cavallotti Gomez
Instituto de Biología y Medicina Experimental, IBYME-CONICET, Ciudad de Buenos Aires 1428, Argentina
1 shared publication - Dalhia Abramovich
Laboratorio de Estudios de la Fisiopatología del Ovario, Instituto de Biología y Medicina Experimental (IBYME-CONICET) , Buenos Aires
1 shared publication - Débora Juana Cohen
Instituto de Biología y Medicina Experimental (IBYME), Fundación IBYME, Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Ciudad Autónoma de Buenos Aires, Argentina
1 shared publication - Eugenia Matzkin
Instituto de Biología y Medicina Experimental (IByME) – CONICET, Buenos Aires, Argentina
1 shared publication - Fernanda Parborell
IBYME, CONICET, Buenos Aires, Argentina
1 shared publication
Latest Publications
- 20 September 2025
- Published by Springer Nature in GeroScience
- Vol. 48 (2) , 1623-1647
Exploring the impact of metformin on testicular aging in Syrian hamsters
Biochemical and molecular mechanisms associated with testicular aging are still poorly understood. Here, using the Syrian hamster as a natural model of aging, we observed a disturbed spermatogenesis with reduction of the testicular weight and the gonadosomatic index, altered histology including tubular wall fibrosis, increased collagen deposition, and diminished steroidogenesis in testes of aged animals. These changes took place in parallel with an increase in the levels of inflammatory and oxidative stress markers and a reduction in the cell proliferative, survival, DNA repair, and autophagic capacities. Metformin, beyond its current clinical applications, has been proposed as an anti-aging drug. In vitro incubations of testicular fragments from old hamsters with metformin revealed beneficial effects of this drug on the testicular inflammatory-oxidative state together with stimulation of autophagy and cell ability to fix DNA damage. However, in vivo daily oral administration of metformin to aged hamsters for 2 months in a dose equivalent to that usually received by patients with type 2 diabetes mellitus, reduced body and testicular weights, gonadosomatic index and blood glucose, concomitantly with increased levels of indicators of testicular inflammation, oxidation and fibrosis, decreased signs of autophagy, steroidogenesis and DNA repair capacity, and impaired spermatogenesis. Overall, while in vitro studies suggested beneficial effects of metformin in the aging testis evidenced through anti-inflammatory, anti-oxidant, and pro-autophagic actions, in vivo experiments in aged hamsters supplemented with metformin exhibited completely opposite effects. Therefore, the future of metformin as a testicular anti-aging agent should be further investigated, thoroughly reconsidered and, should the need arise, disregarded.
- 20 September 2025
- Published by Springer Nature in GeroScience
- Vol. 48 (2) , 1623-1647
Exploring the impact of metformin on testicular aging in Syrian hamsters
Biochemical and molecular mechanisms associated with testicular aging are still poorly understood. Here, using the Syrian hamster as a natural model of aging, we observed a disturbed spermatogenesis with reduction of the testicular weight and the gonadosomatic index, altered histology including tubular wall fibrosis, increased collagen deposition, and diminished steroidogenesis in testes of aged animals. These changes took place in parallel with an increase in the levels of inflammatory and oxidative stress markers and a reduction in the cell proliferative, survival, DNA repair, and autophagic capacities. Metformin, beyond its current clinical applications, has been proposed as an anti-aging drug. In vitro incubations of testicular fragments from old hamsters with metformin revealed beneficial effects of this drug on the testicular inflammatory-oxidative state together with stimulation of autophagy and cell ability to fix DNA damage. However, in vivo daily oral administration of metformin to aged hamsters for 2 months in a dose equivalent to that usually received by patients with type 2 diabetes mellitus, reduced body and testicular weights, gonadosomatic index and blood glucose, concomitantly with increased levels of indicators of testicular inflammation, oxidation and fibrosis, decreased signs of autophagy, steroidogenesis and DNA repair capacity, and impaired spermatogenesis. Overall, while in vitro studies suggested beneficial effects of metformin in the aging testis evidenced through anti-inflammatory, anti-oxidant, and pro-autophagic actions, in vivo experiments in aged hamsters supplemented with metformin exhibited completely opposite effects. Therefore, the future of metformin as a testicular anti-aging agent should be further investigated, thoroughly reconsidered and, should the need arise, disregarded.
- 16 September 2025
- Published by Springer Nature in Journal of Assisted Reproduction and Genetics
- Vol. 42 (11) , 3695-3712
Melatonin alleviates cyclophosphamide-induced ovarian toxicity in mice
Purpose Anticancer drugs like cyclophosphamide (CTX) cause severe ovarian damage, often leading to infertility, while current fertility preservation methods are invasive and costly. This study investigates whether melatonin (MEL) can protect ovarian function in a CTX-induced premature ovarian failure (POF) mouse model, offering a potential noninvasive and cost-effective fertoprotective approach. Methods A CTX-induced POF mouse model was used to assess MEL’s protective effects. Ovarian function was evaluated by analyzing follicle counts, ovarian weight, serum hormone levels, apoptosis markers, histopathological changes, vascular integrity, and antioxidant defences. Results MEL coadministration increased the proportion of primary and antral follicles (p < 0.01 and p < 0.05) while reducing atretic follicles (p < 0.05). MEL preserved ovarian weight, maintained primordial follicle counts, and prevented CTX-induced hormone level reductions. MEL also enhanced AMH-positive follicle percentage, reduced apoptosis, and mitigated vascular injury, fibrosis, and blood vessel hyalinization (p < 0.05). Furthermore, MEL restored uterine tissue architecture, improved vascular health by recruiting pericytes and smooth muscle cells (p < 0.05), and enhanced antioxidant defenses through increased expression of superoxide dismutase 1 (SOD1) (p < 0.05). Conclusion MEL effectively preserves ovarian function in a CTX-induced POF model by protecting follicular development, hormonal balance, vascular integrity, and antioxidant defenses. These findings highlight MEL as a promising, noninvasive, and cost-effective strategy for fertility preservation in female cancer patients undergoing chemotherapy.
- 16 September 2025
- Published by Springer Nature in Journal of Assisted Reproduction and Genetics
- Vol. 42 (11) , 3695-3712
Melatonin alleviates cyclophosphamide-induced ovarian toxicity in mice
Purpose Anticancer drugs like cyclophosphamide (CTX) cause severe ovarian damage, often leading to infertility, while current fertility preservation methods are invasive and costly. This study investigates whether melatonin (MEL) can protect ovarian function in a CTX-induced premature ovarian failure (POF) mouse model, offering a potential noninvasive and cost-effective fertoprotective approach. Methods A CTX-induced POF mouse model was used to assess MEL’s protective effects. Ovarian function was evaluated by analyzing follicle counts, ovarian weight, serum hormone levels, apoptosis markers, histopathological changes, vascular integrity, and antioxidant defences. Results MEL coadministration increased the proportion of primary and antral follicles (p < 0.01 and p < 0.05) while reducing atretic follicles (p < 0.05). MEL preserved ovarian weight, maintained primordial follicle counts, and prevented CTX-induced hormone level reductions. MEL also enhanced AMH-positive follicle percentage, reduced apoptosis, and mitigated vascular injury, fibrosis, and blood vessel hyalinization (p < 0.05). Furthermore, MEL restored uterine tissue architecture, improved vascular health by recruiting pericytes and smooth muscle cells (p < 0.05), and enhanced antioxidant defenses through increased expression of superoxide dismutase 1 (SOD1) (p < 0.05). Conclusion MEL effectively preserves ovarian function in a CTX-induced POF model by protecting follicular development, hormonal balance, vascular integrity, and antioxidant defenses. These findings highlight MEL as a promising, noninvasive, and cost-effective strategy for fertility preservation in female cancer patients undergoing chemotherapy.